Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, NPT

Premier Pediatric Research Center Adopts Complion's eISF Platform to Strengthen Pediatric Research Excellence


SAN ANTONIO, March 26, 2024 /PRNewswire/ -- Complion, LLC, a wholly owned subsidiary of RealTime Software Solutions, LLC and a leader in eRegulatory solutions, proudly announces the latest adoption of its eRegulatory/eISF solutions by a leading, not-for-profit pediatric hospital and active research facility. This collaboration marks a significant milestone, as another of the nation's top 10 pediatric research institutions has chosen Complion's sophisticated eISF system to improve compliance and data management processes across its research endeavors.

As a leading pediatric medical center overseeing almost 150 ongoing studies across its research portfolios, this world-class institution sought an exceptional eClinical solution to meet the demands of its complex pediatric clinical research. Complion was chosen because of its ability to simplify research workflows by converting manual, time-consuming tasks into automated, efficient operations. This selection highlights Complion's focus on advancing clinical trial management, optimizing processes, and reducing administrative staff workloads. 

"We are thrilled to see leading pediatric medical centers adopting our platform. Our team uniquely understands the challenges that they're facing in compliance, and we're thrilled that Complion is becoming the premiere choice," states Rick Arlow, president and founder at Complion. Institutions that have already adopted Complion report a fivefold increase in inspection readiness, a 75% reduction in monitoring interactions, and double the rate of study start-ups for sites, sponsors, and CROs."

Complion's eISF system is distinguished by its targeted design, developed to meet the unique requirements of complex pediatric clinical research. Its user-friendly interface and robust capabilities make it an increasingly preferred choice for research and academic medical centers aiming to streamline their regulatory documentation and enhance operational efficiency.

About RealTime Software Solutions:
RealTime Software Solutions, LLC is a leading provider of innovative SaaS solutions that help clinical research sites, site networks, sponsors and CROs easily manage complex clinical research processes. The company's products include Clinical Trial Management System (CTMS), eRegulatory document management (eDOCS), electronic data capture for source documents (eSOURCE), participant payments (SitePAY/GlobalPAY), participant engagement solutions (TEXT, eCONSENT and MyStudyManagertm Participant Portal), Complion eRegulatory and eISF, and Devana PROPEL. With a strong track record of empowering research organizations, RealTime Software Solutions is dedicated to creating powerful, user-friendly interfaces that revolutionize how research gets done.

Contact:
Daenya McDonald
Communications Director
[email protected]
(210) 852-4310 x1114

SOURCE RealTime Software Solutions


These press releases may also interest you

1 jun 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of its novel drug candidate...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major...

1 jun 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

1 jun 2024
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with...

1 jun 2024
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today...



News published on and distributed by: